Screener
Relmada Therapeutics, Inc. RLMD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$19.05M-8.5% | -$19.87M-6.5% | -$10.09M+53.6% | -$9.87M+44.5% | -$17.56M+19.6% | ||
| $956.19K-73.2% | $2.37M-64.7% | $3.61M-54.6% | $4.35M-39.6% | $3.57M-56.9% | ||
| -$15.07M+16.6% | -$14.6M-65.9% | -$6.72M+59.6% | -$6.4M+51.7% | -$18.07M-38.6% | ||
| -$135.23M-980% | -$76.93M-778% | $6.75M-58.2% | $6.68M-52.3% | $15.36M+52.7% | ||
| $3.36M— | —— | —— | —— | —— | ||
| $156.57M— | $93.64M+54,387% | —— | —— | —— | ||
| $6.28M+332% | —— | —— | —— | -$2.71M+1.8% |
FAQ
- How much cash does Relmada Therapeutics, Inc. generate?
- Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.
- Where does Relmada Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.